In a welcome move, BioNTech ADR saw its Relative Strength Rating rise from 69 to 77 on Wednesday.
When To Sell Stocks To Lock In Profits And Minimize Losses
This exclusive rating from Investor's Business Daily tracks price movement with a 1 (worst) to 99 (best) score. The score shows how a stock's price movement over the trailing 52 weeks compares to all the other stocks in our database.
Decades of market research shows that the market's biggest winners often have an 80 or better RS Rating in the early stages of their moves. See if BioNTech ADR can continue to rebound and clear that threshold.
Now is not an ideal time to jump in since it isn't near a proper buy zone, but see if the stock manages to establish and enter a buying range in heavy volume.
The company showed 0% EPS growth last quarter, while sales growth came in at 123%.
The company earns the No. 144 rank among its peers in the Medical-Biomed/Biotech industry group. Aurinia Pharmaceuticals, Halozyme Therapeutics and Incyte are among the top 5 highly rated stocks within the group.
This article was created automatically with Stats Perform's Wordsmith software using data and article templates supplied by Investor's Business Daily. An IBD journalist may have edited the article.
RELATED:
Biotech And Pharmaceutical Industry And Stock News
IBD Stock Rating Upgrades: Rising Relative Strength
Why Should You Use IBD's Relative Strength Rating?
How Relative Strength Line Can Help You Judge A Stock
Ready To Grow Your Investing Skills? Join An IBD Meetup Group!
